2025 Q4 -tulosraportti
17 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Irtoamispäivä 27.3.
3,79%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 071 292
Myynti
Määrä
2 451 087
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 429 | - | - | ||
| 3 790 | - | - | ||
| 100 | - | - | ||
| 100 | - | - | ||
| 1 | - | - |
Ylin
310,75VWAP
Alin
298,5VaihtoMäärä
1 720,1 5 688 416
VWAP
Ylin
310,75Alin
298,5VaihtoMäärä
1 720,1 5 688 416
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·8 t sitten · MuokattuSemaglutide-based medicines (e.g. Ozempic, Wegovy, Rybelsus) These are some of Novo Nordisk's largest products globally. Semaglutide patents begin to expire in several countries in 2026, which will open the door for generic or biosimilar products in these regions. Insights;Gate + 1 Examples of early expirations: China → 2026 annualreport.novonordisk.com India, Brazil, Canada and Turkey are also expected to have semaglutide protection expire in 2026, so generics can enter the market there (based on several analysis summaries). In the USA and Europe, the main patents last longer, typically until around 2031-2032 for semaglutide active ingredients, although there may be differences for different patent families and formulations. And some of the Semaglutide patents begin to expire next month. And then there is Eli Lilly who will definitely get their pill on the market in April. I'm thinking that unfortunately it only goes one way for the next while ugh
·46 min sittenAmycretin gives approx. 25% weight loss in just half a year. I think that's extremely fast. The question is probably by now, is it even healthy to lose weight so quickly?
·9 t sittenStay calm in the boat. If we go below 300, it's just to buy more. If we just look beyond our nose, then in Novo we have a good case.
·52 min sittenI don't understand the belief that Novo, specifically, should be the best investment. Gone from 1000 to 300 in under 2 years, patent expiry, price pressure, massive competition in the weight loss market in a few years, and expected negative growth. I myself have some Novo in funds, but it's not a stock I see the greatest potential in at this price level. Why Novo, though?
·10 t sittenUS sends Novo further down. By Easter it will be down to 250.
·8 t sitten · MuokattuI take the claim at face value in this evaluation. Price 250 corresponds to P/E ~12. NN is challenged in the medium term, while revenue and profit dive ~10% in the very short term. In light of the above, a fair price for the company "as is" would be P/E ~12-16, depending on risk premium. Price 250 is therefore not unrealistic. That is the hard truth. Whether the price is slaughtered depends on how many throw good money after bad (read: figurative meaning). Unfortunately
·10 t sittenIn my opinion, there has always been an idea that the entire WEIGHT LOSS market should be divided into 3: Novo, Eli and other candidates. The copies take a large part of Novo's and Eli's market share, but also significantly complicate the candidates' entry! Novo's earnings have run a bit ahead, as Ozempic has been used as weight loss medicine. We now see that Wegovy is taking this market from Ozempic. Ozempic is probably a remedy for diabetics and this market is still growing. My own opinion is that the total diabetes and weight loss market is growing. Novo remains a large part of this because they have muscle and pipeline. Whether Novo has 20, 25, or 50% market share is not the decisive factor, but that they maintain a reasonable earning.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
17 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Irtoamispäivä 27.3.
3,79%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sitten · MuokattuSemaglutide-based medicines (e.g. Ozempic, Wegovy, Rybelsus) These are some of Novo Nordisk's largest products globally. Semaglutide patents begin to expire in several countries in 2026, which will open the door for generic or biosimilar products in these regions. Insights;Gate + 1 Examples of early expirations: China → 2026 annualreport.novonordisk.com India, Brazil, Canada and Turkey are also expected to have semaglutide protection expire in 2026, so generics can enter the market there (based on several analysis summaries). In the USA and Europe, the main patents last longer, typically until around 2031-2032 for semaglutide active ingredients, although there may be differences for different patent families and formulations. And some of the Semaglutide patents begin to expire next month. And then there is Eli Lilly who will definitely get their pill on the market in April. I'm thinking that unfortunately it only goes one way for the next while ugh·46 min sittenAmycretin gives approx. 25% weight loss in just half a year. I think that's extremely fast. The question is probably by now, is it even healthy to lose weight so quickly?
- ·9 t sittenStay calm in the boat. If we go below 300, it's just to buy more. If we just look beyond our nose, then in Novo we have a good case.·52 min sittenI don't understand the belief that Novo, specifically, should be the best investment. Gone from 1000 to 300 in under 2 years, patent expiry, price pressure, massive competition in the weight loss market in a few years, and expected negative growth. I myself have some Novo in funds, but it's not a stock I see the greatest potential in at this price level. Why Novo, though?
- ·10 t sittenUS sends Novo further down. By Easter it will be down to 250.·8 t sitten · MuokattuI take the claim at face value in this evaluation. Price 250 corresponds to P/E ~12. NN is challenged in the medium term, while revenue and profit dive ~10% in the very short term. In light of the above, a fair price for the company "as is" would be P/E ~12-16, depending on risk premium. Price 250 is therefore not unrealistic. That is the hard truth. Whether the price is slaughtered depends on how many throw good money after bad (read: figurative meaning). Unfortunately
- ·10 t sittenIn my opinion, there has always been an idea that the entire WEIGHT LOSS market should be divided into 3: Novo, Eli and other candidates. The copies take a large part of Novo's and Eli's market share, but also significantly complicate the candidates' entry! Novo's earnings have run a bit ahead, as Ozempic has been used as weight loss medicine. We now see that Wegovy is taking this market from Ozempic. Ozempic is probably a remedy for diabetics and this market is still growing. My own opinion is that the total diabetes and weight loss market is growing. Novo remains a large part of this because they have muscle and pipeline. Whether Novo has 20, 25, or 50% market share is not the decisive factor, but that they maintain a reasonable earning.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 071 292
Myynti
Määrä
2 451 087
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 429 | - | - | ||
| 3 790 | - | - | ||
| 100 | - | - | ||
| 100 | - | - | ||
| 1 | - | - |
Ylin
310,75VWAP
Alin
298,5VaihtoMäärä
1 720,1 5 688 416
VWAP
Ylin
310,75Alin
298,5VaihtoMäärä
1 720,1 5 688 416
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
2025 Q4 -tulosraportti
17 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
7,95 DKK/osake
Irtoamispäivä 27.3.
3,79%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sitten · MuokattuSemaglutide-based medicines (e.g. Ozempic, Wegovy, Rybelsus) These are some of Novo Nordisk's largest products globally. Semaglutide patents begin to expire in several countries in 2026, which will open the door for generic or biosimilar products in these regions. Insights;Gate + 1 Examples of early expirations: China → 2026 annualreport.novonordisk.com India, Brazil, Canada and Turkey are also expected to have semaglutide protection expire in 2026, so generics can enter the market there (based on several analysis summaries). In the USA and Europe, the main patents last longer, typically until around 2031-2032 for semaglutide active ingredients, although there may be differences for different patent families and formulations. And some of the Semaglutide patents begin to expire next month. And then there is Eli Lilly who will definitely get their pill on the market in April. I'm thinking that unfortunately it only goes one way for the next while ugh·46 min sittenAmycretin gives approx. 25% weight loss in just half a year. I think that's extremely fast. The question is probably by now, is it even healthy to lose weight so quickly?
- ·9 t sittenStay calm in the boat. If we go below 300, it's just to buy more. If we just look beyond our nose, then in Novo we have a good case.·52 min sittenI don't understand the belief that Novo, specifically, should be the best investment. Gone from 1000 to 300 in under 2 years, patent expiry, price pressure, massive competition in the weight loss market in a few years, and expected negative growth. I myself have some Novo in funds, but it's not a stock I see the greatest potential in at this price level. Why Novo, though?
- ·10 t sittenUS sends Novo further down. By Easter it will be down to 250.·8 t sitten · MuokattuI take the claim at face value in this evaluation. Price 250 corresponds to P/E ~12. NN is challenged in the medium term, while revenue and profit dive ~10% in the very short term. In light of the above, a fair price for the company "as is" would be P/E ~12-16, depending on risk premium. Price 250 is therefore not unrealistic. That is the hard truth. Whether the price is slaughtered depends on how many throw good money after bad (read: figurative meaning). Unfortunately
- ·10 t sittenIn my opinion, there has always been an idea that the entire WEIGHT LOSS market should be divided into 3: Novo, Eli and other candidates. The copies take a large part of Novo's and Eli's market share, but also significantly complicate the candidates' entry! Novo's earnings have run a bit ahead, as Ozempic has been used as weight loss medicine. We now see that Wegovy is taking this market from Ozempic. Ozempic is probably a remedy for diabetics and this market is still growing. My own opinion is that the total diabetes and weight loss market is growing. Novo remains a large part of this because they have muscle and pipeline. Whether Novo has 20, 25, or 50% market share is not the decisive factor, but that they maintain a reasonable earning.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 071 292
Myynti
Määrä
2 451 087
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 429 | - | - | ||
| 3 790 | - | - | ||
| 100 | - | - | ||
| 100 | - | - | ||
| 1 | - | - |
Ylin
310,75VWAP
Alin
298,5VaihtoMäärä
1 720,1 5 688 416
VWAP
Ylin
310,75Alin
298,5VaihtoMäärä
1 720,1 5 688 416
Välittäjätilasto
Dataa ei löytynyt